Summarizing the data of more than 400 cases including cancer sera, sera of patients with non-cancer diseases and healthy controls, we found an overall 10% increase of autoantibody response to SART1 in cancer sera as compared to normal controls and non-cancer diseases. This evidence concerns the gene SART1 and cancer.